Electrophysiological characterization of axoCells™ hiPSC-derived ventricular cardiomyocytes using physiological solutions on QPatch

Cardiovascular disease remains the leading global cause of death, and the evaluation of potential cardiotoxicity continues to be a major challenge and expense in early drug development. The human-induced pluripotent stem-cell (hiPSC) technology was developed in 2007, and hiPSC-derived cardiomyocytes (hiPSC-CMs) have since then been evaluated as a promising model system for cardiac drug screening, disease modelling and cardiotoxicity testing.

Automated patch clamp (APC) systems enable high-throughput, precise electrophysiological measurements of cardiac ion channels across large hiPSC-CM populations, accelerating screening workflows of these key therapeutic and safety targets.
This study employs the Sophion QPatch APC platform to biophysically and pharmacologically evaluate cardiac ion channels and paced action potentials in axoCells™ ventricular hiPSC-CMs, to highlight the potential of this technology in cardiac safety and drug discovery.